Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Investor Presentation (September 2023)
18 slides from Marinomed Biotech's investor presentation, Sep 6, 2023
Slide 1: Marinomed Biotech AG Company Presentation
Marinomed Biotech AG Company Presentation September 2023
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Marinomed at a glance
Marinomed at a glance Publicly listed biopharmaceutical company located in Korneuburg, Austria 2006 2008 2016 2019 2021 2022 Foundation Launch of Carragelose Invention of IPO and Marinosolv Marinosolv deal and Deal with Marinosolv clinical validation Solv4U launch Procter & Gamble 8.2% 8.0% Hermann
Slide 4: Business Model
Business Model Lean organization & existing business RESEARCH & DEVELOPMENT SALE OF GOODS Research & Pre-clinical Early clinical Supply chain Innovation development development organization Intellectual property High-value products Revenue through license deals Revenue through (upfront, milestones &
Slide 5: Equity Story
Equity Story Solid existing business, growth perspective through late-stage pipeline assets • Experienced management team • Solid revenue from marketed product portfolio • Three key assets in partnering: • Carragelose portfolio • Budesolv • Tacrosolv • Lean and efficient business model: cost-efficie
Slide 6: Therapeutic Areas
Therapeutic Areas Proven track record with clinically validated and patent-protected technologies VIROLOGY IMMUNOLOGY • Carragelose from red seaweed: protective • Marinosolv technology: solubilization for layer with multi-use potential hydrophobic compounds • Clinically validated broad-spectrum Susp
Slide 7: Carragelose overview
Carragelose overview Mode of action In-vitro data against respiratory viruses (selection) Rhinoviruses Coronaviruses, including SARS- CoV2 Influenzaviruses A, B Parainfluenza viruses Respiratory syncytial virus (RSV) Without Carragelose: With Carragelose: Virus enters mucosal cell Barrier prevents i
Slide 8: Carragelose
Carragelose Moisturizing and protective layer against viruses and pollen – multi-use potential Viral respiratory diseases Eye care • Blocking numerous • Lubricating respiratory viruses • Relief for dry eyes • Clinically validated • Virus-blocking properties: • Marketed targeting adenoviral keratocon
Slide 9: Marinosolv overview
Marinosolv overview Mode of action Benefits • Solubilization of poorly water- soluble compounds • Significantly increases bioavailability • Dose reduction: Reduces side effects • Faster onset of action • Eco-friendly: Reduces pharmaceutical compounds in wastewater • Clinically validated • Patent pro
Slide 10: Solv4U overview
Solv4U overview PHASE I PHASE II PHASE III PHASE IV FEASIBILITY FORMULATION PRECLINICAL & TECH TRANSFER DEVELOPMENT CLINICAL STUDIES Enhanced solubility of target Optimize formulation & Target Product Profile (TPP) & Enable manufacturing at compound with Marinosolv® Provide non-GMP material for stud
Slide 11: Pipeline
Pipeline Late-stage projects with low risk and high upside potential © Marinomed Biotech AG 11
Slide 12: Highlights year-to-date 2023
Highlights year-to-date 2023 Progress and new developments EUR 5.2 m Market Solv4U New product revenues authorization Partnership Strong H1 Carragelose eye For Carragelose With SPH Sine Carragelose drops – launch nasal spray in Pharmaceutical revenues planned for 2024 Mexico Laboratories © Marinomed
Slide 13: Record H1 revenues
Record H1 revenues Carragelose strong in H1 with post-pandemic slow-down of customer orders Development of half-yearly revenues (m€) Comments Historical numbers • Revenues rose from €4.9m to €5.2m (+7%) 2.1* • EBIT slightly decreased from €2.5m to €2.9m due to higher R&D expenses 5.8 6.3 6.4 4.5 4.9
Slide 14: Cash visibility into 2024
Cash visibility into 2024 Carragelose revenues reducing cash burn, repayment of loans ongoing •1 Operations mainly consisting of personnel costs and R&D expenses; MDR switch temporarily also contributing 1 1 • 2 Strong quarters in terms of Carragelose revenue contributing 1 significantly to reducing
Slide 15: Marinomed strategic priorities
Marinomed strategic priorities Focus on revenue generation with existing products and product candidates INHALEEN • Long-term adherence to our mission MAM-1004-2 • Funding promising pipeline programs through own cash flows NEW ASSETS FOR ADDITIONAL GROWTH TACROSOLV BUDESOLV • Expanding business with
Slide 16: Carragelose – growth strategy
Carragelose – growth strategy Expansion of territory, indication and product portfolio Target Action item Status / next steps USA → FDA registration USA (Procter & Gamble), Mexico and Territory expansion - registration Mexico → received market approval Brazil (M81) Brazil → ANVISA registration Conti
Slide 17: Immunology – focus on business development
Immunology – focus on business development Expansion of territory, indication and product portfolio Area / Product Action item Status / next steps Complete the BD process and enable Tacrosolv (MAM-1003-1) Run a structured BD process with a partnership within the next 6-12 Inflammatory eye diseases e
Slide 18: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar 2023 November 21, 2023 Publication of the Results Q1-3 2023 Stephanie Kniep Investor Relations phone: +43 2262 90300 226 e-mail: IR@marinomed.com © Marinomed Biotech AG 18
Marinomed Biotech — Investor Presentation (September 2023) on 6ix